Staphylococcus Aureus Bacteremia Clinical Trial
— SABOTOfficial title:
SAB-Support-Study: Can Checklist-based Phone Calls Improve the Quality of Staphylococcus Aureus Bacteraemia (SAB) Management
The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S. aureus bacteraemia (SAB) can improve adherence to our in-house SAB-guidelines (prospective quality- improvement group). In addition, the effects of telephone consultation on the clinical outcome of patients will be examined.
Status | Recruiting |
Enrollment | 124 |
Est. completion date | April 23, 2025 |
Est. primary completion date | January 22, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years - Inpatient treatment at the University Medicine Greifswald university hospital - First diagnosis of SAB in hospital Exclusion Criteria: - SAB already known before admission - Palliative management within 48 hrs after SAB diagnosis - Death within 48 hrs after SAB diagnosis - Hospital discharge within 48hrs after SAB diagnosis |
Country | Name | City | State |
---|---|---|---|
Germany | Greifswald University Medicine | Greifswald |
Lead Sponsor | Collaborator |
---|---|
University Medicine Greifswald |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SOP adherence, calculated as a sum score per patient with the following 8 parameters: | Drawing of follow-up blood cultures 2-3 days after start of adequate antibiotic therapy
Early source control (removal of infected material or drainage of an abscess = 72 hrs) Adequate search for SAB focus and metastatic manifestations TEE in patients with clinical indications (within 4 days of SAB diagnosis) Early start of specific therapy after receipt of results via phone call (=12 hrs) Adequate dosage of antibiotic Sufficient duration of therapy (at least 14 d for uncomplicated bacteremia and 28 d for complicated bacteremia) Combination therapy with Rifampicin or Fosfomycin, when indicated |
Hospital admission until hospital discharge (no later than day 90 after diagnosis) | |
Secondary | Time to specific antimicrobial treatment according to guidelines concerning agent and duration | Hospital admission until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | Time to negativity of follow up blood cultures | Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | Time till TEE is performed (when indicated) | Hospital admission until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | Length of hospital stay after SAB diagnosis | Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | In-hospital mortality (all patients) | Hospital admission until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | In-hospital mortality (because of SAB complications) | Hospital admission until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | Hospital readmission until day 30 after SAB diagnosis (all patients) | Day of SAB diagnosis until day 30 after diagnosis | ||
Secondary | Hospital readmission until day 30 after SAB diagnosis (because of SAB complications) | Day of SAB diagnosis until day 30 after diagnosis | ||
Secondary | Hospital readmission until day 90 after SAB diagnosis (all patients) | Day of SAB diagnosis until day 90 after diagnosis | ||
Secondary | Hospital readmission until day 90 after SAB diagnosis (because of SAB complications) | Day of SAB diagnosis until day 90 after diagnosis | ||
Secondary | 90-day all-cause mortality | Day of SAB diagnosis until day 90 after diagnosis | ||
Secondary | 90-day mortality because of SAB complications | Day of SAB diagnosis until day 90 after diagnosis | ||
Secondary | Relapse of bacteremia until day 90 after diagnosis | Day of SAB diagnosis until day 90 after diagnosis | ||
Secondary | Quality of discharge summary (documentation and treatment plan), calculated as a sum score | Hospital admission until hospital discharge (no later than day 90 after diagnosis) | ||
Secondary | Infectious diseases consultation, when indicated (yes/no) | Hospital admission until hospital discharge (no later than day 90 after diagnosis) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05862025 -
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
|
N/A | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Recruiting |
NCT00622882 -
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT06168474 -
Evaluating Simplified Layered Consent for Clinical Trials
|
N/A | |
Completed |
NCT03163446 -
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
|
Phase 2 | |
Not yet recruiting |
NCT06336824 -
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
|
Phase 3 | |
Completed |
NCT02357966 -
A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
|
Phase 1/Phase 2 | |
Recruiting |
NCT04886284 -
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
|
Phase 2 | |
Terminated |
NCT03089697 -
Phase IIa Clinical Study of N-Rephasin® SAL200
|
Phase 2 | |
Recruiting |
NCT03514446 -
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Withdrawn |
NCT03761953 -
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
|
Phase 4 | |
Recruiting |
NCT02098850 -
Staphylococcus Aureus Bacteraemia in Adults
|
N/A | |
Completed |
NCT01701219 -
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Recruiting |
NCT05137119 -
Staphylococcus Aureus Network Adaptive Platform Trial
|
Phase 4 | |
Completed |
NCT03908086 -
Bloodstream Infections in Patients With Rheumatoid Arthritis
|
||
Terminated |
NCT04160468 -
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
|
Phase 3 | |
Completed |
NCT03138733 -
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
|
Phase 3 | |
Completed |
NCT02476487 -
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT05184764 -
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
|
Phase 1/Phase 2 | |
Completed |
NCT01971762 -
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
|
N/A |